St George’s University Hospitals NHS Foundation Trust

Running trials

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

  NCT07386418· Imperial College London· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Not yet recruiting

  Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

  NCT06920316· Phase 4· St. George's Hospital, London· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Active, not recruiting

  Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention

  NCT07891988· University of Leicester· Source

• Recruiting

  Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

  NCT06823466· University of L'Aquila· Source

• Recruiting

  Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

  NCT06435156· Phase 2· University of Dundee· Source

• Recruiting

  Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart

  NCT06505798· University College, London· Source

• Active, not recruiting

  Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

  NCT06149650· Cardiovascular and Interventional Radiological Society of Europe· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis

  NCT06223893· University College, London· Source

• Enrolling by invitation

  Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

  NCT06066580· Phase 2· Edgewise Therapeutics, Inc.· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Recruiting

  A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

  NCT06461208· Phase 3· King's College London· Source

• Recruiting

  DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

  NCT05389774· Nottingham University Hospitals NHS Trust· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  NCT06311708· Tenaya Therapeutics· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

  NCT05494606· AbbVie· Source

• Recruiting

  Lymphatic Mapping Of Oropharyngeal Cancer

  NCT04498221· University College, London· Source

• Recruiting

  The South London Stroke Register: Improving the Lives of Stroke Survivors With Data

  NCT05298436· Guy's and St Thomas' NHS Foundation Trust· Source

• Active, not recruiting

  Precise Procedural and PCI Plan (P4)

  NCT05253677· CoreAalst BV· Source

• Active, not recruiting

  ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

  NCT04695080· Phase 2/3· Queen Mary University of London· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Cytokinetics· Source

• Recruiting

  Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

  NCT04302870· Phase 2/3· University of Edinburgh· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Melanoma and Skin Cancer Trials Limited· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG

  NCT03805048· Amsterdam UMC, location VUmc· Source

• Active, not recruiting

  Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

  NCT03674307· University of British Columbia· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· Phase 3· AbbVie· Source

• Active, not recruiting

  A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

  NCT02130362· AbbVie· Source

• Active, not recruiting

  HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

  NCT01915615· University of Virginia· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Coronary artery disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Heart failure2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver cirrhosis2 recruiting
• Stroke2 recruiting
• ALS (motor neurone disease)1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Head and neck cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Peripheral artery disease1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Terminated

  Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine

  NCT05843721· Chordate Medical· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes

  NCT05009602· Imperial College London· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina

  NCT05142215· Mid and South Essex NHS Foundation Trust· Source

• Completed

  Improved Diagnostics for Paediatric Tuberculosis

  NCT06944561· St George's, University of London· Source

• Completed

  Multimodality Assessment of Ventricular Scar Arrhythmogenicity.

  NCT04632394· St George's, University of London· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  Percutaneous Deep Vein Arterialization Post-Market Study

  NCT03807661· LimFlow SA· Source

• Completed

  Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

  NCT03648489· Phase 2· Imperial College London· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease25 works · 1 trial
• Ventricular tachycardia8 works · 1 trial
• Coeliac disease5 works · 0 trials